Shingles prevention vaccine study for kids with kidney transplants
Part of Infections clinical trials.
This study tests whether an investigational shingles (herpes zoster) vaccine is safe and helps prevent shingles in children who have had a kidney transplant. Because these children take medicines to prevent rejection, the study specifically looks at vaccine effects in this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 17 years old (and weigh at least 6 kg / 13.23 lb)
- Have a kidney transplant done more than 6 months ago (180 days), with kidney function stable per study rules
- Be on ongoing anti-rejection medicines for at least 1 month before starting the study
- Know your chickenpox (varicella) immunity status—either past chickenpox/vaccine, confirmed past infection, or a blood test showing you’ve had it
- If biologically female and able to get pregnant, use reliable birth control starting 30 days before vaccination and continue through 2 months after the vaccine series ends
- Be able to follow study visits and rules (including a 7-day diary before vaccination)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests a new shingles vaccine to make sure each batch works the same way. If you are 40 or older and have never had shingles or the shingles vaccine, you may qualify.
This study tests an experimental shingles vaccine in adults aged 40 and older. It aims to see if the vaccine is safe and helps your body build immunity against shingles.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.